Impact of Chemotherapy Exposure and DNMT3A Variants on Tumor Mutation Burden in Advanced Colorectal Cancer

Tomoya Sudo(Kurume University), Fumihiko Fujita(Japan Society of Laparoscopic Colorectal Surgery), Yusuke Kawamoto(Kurume University), Maako Kikuchi(Kurume University), Kenichi Koushi(Juntendo University), Takahiro Shigaki(National Cancer Center Hospital East), Kenji Fujiyoshi(Kurume University), Sachiko Nagasu(Kurume University), Junya Fukuda(Kurume University), Hirona Shigyou(Kurume University), Toshimitsu Tanaka(Kurume University), Takefumi Yoshida(Kurume University), Satoshi Shimamura(Kurume University), Naohiro Yoshida(Ishikawa Prefectural Central Hospital), Hironori Koga(Kurume University), Keisuke Miwa(Kurume University)
Research Square
October 23, 2025
10.21203/rs.3.rs-7483602/v1
Cited by 0

Related Papers

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer
|JAMA|2023|255
Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging
|Gut|2020|159
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer
|Nature Medicine|2024|108
Recent traction methods for endoscopic submucosal dissection
|World Journal of Gastroenterology|2016|86
High expression of <scp>CD</scp>44v9 and <scp>xCT</scp> in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine
|Cancer Science|2018|83